467 Immunotherapy with 4-1BBL-expressing iPScell-derived myeloid lines

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer

Immune regulation has been shown to be involved in the progressive growth of some murine tumours. Interruption of immune regulatory pathways via activation of 4-1BB or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade appears to be a promising strategy for cancer immunotherapy. In this study, we examined the effectiveness of 4-1BBL-expressing tumor cell vaccine in combination with C...

Immunotherapy against Metastatic Melanoma with Human iPS Cell-Derived Myeloid Cell Lines Producing Type I Interferons.

In recent years, immunotherapy for advanced melanoma has been gaining increased attention. The efficacy of anti-cytotoxic T-lymphocyte antigen 4 antibodies, anti-programmed cell death 1 antibodies, and the BRAF(V600E) kinase inhibitor has been proven in metastatic melanoma. At the same time, adoptive cell transfer has significant effects against metastatic melanoma; however, it is difficult to ...

Preferential T cell Expansion by Artificial Antigen Presenting Cells Expressing 4-1BBL Alone or in Combination with CD80 or CD86

Multimeric forms of 4-1BBL as stimulators of T cells for adoptive immunotherapy

Members of the TNF SuperFamily of ligands (TNFSFs) have significant potential as immuno-oncology therapeutic agents. The TNFSFs are trimeric membrane proteins that can be cleaved into soluble single trimers. While the soluble single trimers can be easily prepared and studied, they have little or no activity in vivo. This deficiency is caused by the need to cluster their cognate receptors in the...

CD28 Reveals a Role for 4-1BBL in Skin Mice and of Mice Lacking Both 4-1BBL and Analysis of 4-1BB Ligand (4-1BBL)-Deficient